Amneal Pharmaceuticals Inc. (AMRX)
Are Medical Stocks Lagging Amneal Pharmaceuticals (AMRX) This Year?
Here is how Amneal Pharmaceuticals (AMRX) and Bayer Aktiengesellschaft (BAYRY) have performed compared to their sector so far this year.
3 Reasons Growth Investors Will Love Amneal (AMRX)
Amneal (AMRX) could produce exceptional returns because of its solid growth attributes.
Does Amneal (AMRX) Have the Potential to Rally 54.16% as Wall Street Analysts Expect?
The mean of analysts' price targets for Amneal (AMRX) points to a 54.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Here is Why Growth Investors Should Buy Amneal (AMRX) Now
Amneal (AMRX) could produce exceptional returns because of its solid growth attributes.
Amneal Pharmaceuticals, Inc. (AMRX) Q1 2025 Earnings Call Transcript
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX ) Q1 2025 Earnings Call May 2, 2025 8:30 AM ET Company Participants Tony DiMeo - Head, Investor Relations Chirag Patel - Co-Founder and Co-Chief Executive Officer Chintu Patel - Co-Founder and Co-Chief Executive Officer Tasos Konidaris - Chief Financial Officer Conference Call Participants David Amsellem - Piper Sandler Les Sulewski - Truist Securities Chris Schott - JPMorgan Operator Good morning and welcome to the Amneal Pharmaceuticals First Quarter 2025 Earnings Call. I'd now like to turn the call over to Amneal's Head of Investor Relations, Tony DiMeo.
Amneal (AMRX) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Amneal (AMRX) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Amneal Pharmaceuticals (AMRX) Q1 Earnings Beat Estimates
Amneal Pharmaceuticals (AMRX) came out with quarterly earnings of $0.21 per share, beating the Zacks Consensus Estimate of $0.15 per share. This compares to earnings of $0.14 per share a year ago.
Amneal Pharmaceuticals (AMRX) Earnings Expected to Grow: Should You Buy?
Amneal (AMRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amneal Pharmaceuticals: Shares Still Feel Significantly Undervalued
Amneal Pharmaceuticals, Inc. seems fundamentally undervalued, with a market cap significantly lower than peers despite similar revenue levels, suggesting potential for substantial stock price appreciation. The company reported strong 2024 financials, with revenues up 17% year-on-year, and forecasts continued growth in 2025, driven by diverse product segments. Amneal is reducing debt effectively, targeting a net debt to EBITDA ratio of 3.6-3.7 in 2025, enhancing financial stability and investor confidence.
Amneal Pharmaceuticals, Inc. (AMRX) Q4 2024 Earnings Call Transcript
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX ) Q4 2024 Earnings Conference Call February 28, 2025 8:30 AM ET Company Participants Tony DiMeo - Head of Investor Relations Chirag Patel - President and Co-Chief Executive Officer Chintu Patel - Co-Chief Executive Officer Tasos Konidaris - Executive Vice President and Chief Financial Officer Joe Renda - Senior Vice President and Chief Commercial Officer, Specialty Jason Daly - Chief Legal Officer Conference Call Participants Chris Schott - J.P. Morgan David Amsellem - Piper Sandler Leszek Sulewski - Truist Securities Balaji Prasad - Barclays Operator Good morning and welcome to the Amneal Pharmaceuticals Fourth Quarter 2024 Earnings Call.
Here's What Key Metrics Tell Us About Amneal (AMRX) Q4 Earnings
While the top- and bottom-line numbers for Amneal (AMRX) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Amneal Pharmaceuticals (AMRX) Q4 Earnings Lag Estimates
Amneal Pharmaceuticals (AMRX) came out with quarterly earnings of $0.12 per share, missing the Zacks Consensus Estimate of $0.15 per share. This compares to earnings of $0.14 per share a year ago.
